7508-04-5

Basic information

• Product Name: 5-(4-methoxyphenyl)pentanoic acid
• Synonyms: 5-(4-methoxyphenyl)pentanoic acid
• CAS NO: 7508-04-5
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.25364
• Mol File: 7508-04-5.mol

Chemical Properties

• Boiling Point: 371.5°Cat760mmHg
• Flash Point: 142.3°C
• Appearance: /
• Density: 1.093g/cm³
• Vapor Pressure: 3.55E-06mmHg at 25°C
• Refractive Index: 1.52
• CAS DataBase Reference: 5-(4-methoxyphenyl)pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-methoxyphenyl)pentanoic acid(7508-04-5)
• EPA Substance Registry System: 5-(4-methoxyphenyl)pentanoic acid(7508-04-5)

Safety Data

• Hazardous Substances Data: 7508-04-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-methoxyphenyl)pentanoic acid is used as an analgesic for its pain-relieving properties, making it suitable for the treatment of conditions such as headaches, menstrual cramps, and other forms of mild to moderate pain.
5-(4-methoxyphenyl)pentanoic acid is used as an anti-inflammatory agent for its ability to reduce inflammation associated with conditions like arthritis, thereby alleviating joint pain and improving mobility.
5-(4-methoxyphenyl)pentanoic acid is used as an antipyretic to reduce fever by lowering the body's temperature in response to illness or infection.
5-(4-methoxyphenyl)pentanoic acid is used in both prescription and over-the-counter medications, available for oral and topical administration, catering to a wide range of consumer needs for pain and inflammation management.

InChI:InChI=1/C12H16O3/c1-15-11-8-6-10(7-9-11)4-2-3-5-12(13)14/h6-9H,2-5H2,1H3,(H,13,14)

Upstream product

• 4609-10-3 5-(4-methoxyphenyl)-5-oxopentanoic acid 
• 301303-19-5 [3-(4-methoxy-phenyl)-propyl]-malonic acid 
• 4654-08-4 5-(4'-hydroxyphenyl)pentanoic acid 
• 77-78-1 dimethyl sulfate 
• 854401-87-9 1,10-bis-(4-methoxy-phenyl)-decane-5,6-diol 
• 546-67-8 lead(IV) tetraacetate 
• 71-43-2 benzene 
• 110146-59-3 1,6-bis-(4-methoxy-phenyl)-hex-1-ene 
• 67-64-1 acetone 
• 108-55-4 glutaric anhydride, 
• 100-66-3 methoxybenzene 
• 5205-39-0 ethyl glutaroyl chloride 
• 47172-89-4 diphenyl glutarate 
• 4648-94-6 5-(4-hydroxy-phenyl)-5-oxo-valeric acid 

Downstream Products

• 4654-08-4 5-(4'-hydroxyphenyl)pentanoic acid 
• 4609-10-3 5-(4-methoxyphenyl)-5-oxopentanoic acid 
• 79023-06-6 5-(4-methoxyphenyl)pentanoic acid ethyl ester 
• 61875-52-3 5-(4-methoxy-phenyl)-valeryl chloride 
• 34665-81-1 5-hydroxy-5-(4-methoxyphenyl)valeric acid δ lactone 
• 14374-54-0 5-(4-methoxyphenyl)pentan-1-ol 
• 127047-17-0 5-(4-methoxyphenyl)pentan-1-al 
• 104489-49-8 1-[5-(4-Hydroxy-phenyl)-pentyl]-1,3-dihydro-imidazole-2-thione 
• 104489-46-5 1-[5-(4-Methoxy-phenyl)-pentyl]-1,3-dihydro-imidazole-2-thione 
• 14469-84-2 1-(para-anisyl)-5-bromopentane 
• 4626-83-9 5-(2,4-dinitro-phenylhydrazono)-5-(4-methoxy-phenyl)-valeric acid 
• 4280-60-8 1,10-bis(4-methoxyphenyl)decane 
• 854401-87-9 1,10-bis-(4-methoxy-phenyl)-decane-5,6-diol 

Relevant articles and documents

Combined Photoredox/Enzymatic C?H Benzylic Hydroxylations

Chemical transformations that install heteroatoms into C?H bonds are of significant interest because they streamline the construction of value-added small molecules. Direct C?H oxyfunctionalization, or the one step conversion of a C?H bond to a C?O bond, could be a highly enabling transformation due to the prevalence of the resulting enantioenriched alcohols in pharmaceuticals and natural products,. Here we report a single-flask photoredox/enzymatic process for direct C?H hydroxylation that proceeds with broad reactivity, chemoselectivity and enantioselectivity. This unified strategy advances general photoredox and enzymatic catalysis synergy and enables chemoenzymatic processes for powerful and selective oxidative transformations.

Heterocyclization involving benzylic C(sp3)-H functionalization enabled by visible light photoredox catalysis

A general and efficient method for heterocyclization involving benzylic C(sp3)-H functionalization enabled by visible light photoredox catalysis to access a wide range of structurally diverse oxygen as well as nitrogen heterocycles up to a gram scale is reported. The potential application of this new methodology is demonstrated by the total synthesis of (-)-codonopsinine and (+)-centrolobine. Herein it is proposed that selectfluor, unlike a fluorinating reagent, acts as an oxidative quencher and a hydrogen radical acceptor.

Ni-Catalyzed Carboxylation of Unactivated Alkyl Chlorides with CO2

A catalytic carboxylation of unactivated primary, secondary, and tertiary alkyl chlorides with CO2 at atmospheric pressure is described. This protocol represents the first intermolecular cross-electrophile coupling of unactivated alkyl chlorides, thus leading to new knowledge in the cross-coupling arena.

Racemic total synthesis of dactyloidin and demethyldactyloidin through the dl-proline-catalyzed Knoevenagel condensation/[4 + 2] cycloaddition cascade

An efficient approach towards the first racemic total synthesis of dactyloidin (2) and demethyldactyloidin (3) is described. Their oxygen-bridged tricyclic ketal systems were rapidly constructed by using a remarkable biomimetic Knoevenagel condensation/[4 + 2] cycloaddition cascade as the critical strategy and the 1,5-dicarbonyl segment was assembled by Grignard addition.

Ni-catalyzed carboxylation of unactivated primary alkyl bromides and sulfonates with CO2

A Ni-catalyzed carboxylation of unactivated primary alkyl bromides and sulfonates with CO2 at atmospheric pressure is described. The method is characterized by its mild conditions and remarkably wide scope without the need for air- or moisture-sensitive reagents, which make it a user-friendly and operationally simple protocol en route to carboxylic acids.

New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2

Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as an important pharmaceutical target. Selective and potent GVIA iPLA2 inhibitors can be used to study its role in various neurological diso

Discovery of synthetic methoxy-substituted 4-phenylbutyric acid derivatives as chemical chaperones

In this study, we evaluated the chemical chaperone activity of synthetic 4-phenylbutyric acid (4-PBA) derivatives. These derivatives have a methoxy group at the benzene ring and/or longer or shorter fatty acid portions. Several 4-PBA derivatives demonstrated higher antiaggregation activity than 4-PBA. Moreover, 4-(4-methoxyphenyl)butanoic acid (7b) showed protective effects against endoplasmic reticulum stress-induced neuronal cell death.

G-PROTEIN-CONJUGATED RECEPTOR AGONIST

Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or - NR3- [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].

BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR

A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): (wherein n is 3 or 4; R represents ethyl or hydrogen; and R 1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are an intermediate for the compound and a process for producing the compound.

Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists

This paper describes the synthesis and biological evaluation of a series of straight chain analogs of a compound (1) that was previously synthesized in our research program. These compounds, which are T-type calcium channel antagonists, exhibits potent anti-proliferative activity against a variety of cancer cells. A structure-activity relationship of these analogs against a variety of cancer cells has provided insight into a logical pharmacophore for this series of compounds. Furthermore, this series of compounds has presented itself as a set of novel, concentration dependent, dual action agonists/antagonists for the T-type calcium channel.